EXEL
Exelixis, Inc.
21.83
USD
This page is just a preview of the data found in TrendSpider’s full version
Exelixis, Inc. stock is up 6.02% since 30 days ago. The next earnings date is Feb 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 58.33% of the previous 23 November’s closed higher than October. In the last 10 Unusual Options Trades, there were 5 CALLs, 5 PUTs. 50% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 20 Oct 15:57 | 20 Oct, 2023 | 11.00 | 197 | ||
| 23 Oct 16:54 | 19 Jan, 2024 | 18.00 | 4677 | ||
| 23 Oct 16:55 | 16 Feb, 2024 | 18.00 | 768 | ||
| 26 Oct 15:51 | 16 Feb, 2024 | 16.00 | 0 | ||
| 26 Oct 17:25 | 19 Jan, 2024 | 20.00 | 27838 | ||
| 14 Nov 16:44 | 19 Jan, 2024 | 20.00 | 1627 | ||
| 14 Nov 16:44 | 16 Feb, 2024 | 20.00 | 130 | ||
| 14 Nov 16:46 | 16 Feb, 2024 | 23.00 | 139 | ||
| 16 Nov 18:42 | 19 Jan, 2024 | 22.00 | 1534 | ||
| 17 Nov 14:45 | 19 Jan, 2024 | 20.00 | 5020 |
Exelixis, Inc. focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. Its products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma.
